Search

Precisio Biotix Therapeutics and the Mayo Clinic have announced their first patient dosed with ClyO staph lysin for multidrug-resistant prosthetic joint infection treatment.

Precisio Biotix Therapeutics (Delaware-based biotech) announced a newly awarded Gates Foundation grant for engineered lysin discovery targeting bacterial vaginosis.

Proteon Pharmaceuticals (Łódź, Poland) shared that BAFASAL®, its phage-based feed additive for poultry, has received a majority vote from EU Member States, moving it closer to EU authorisation. Once finalized, it will become the first phage

Another successful phage therapy clinical trial! Armata Pharmaceuticals and colleagues has announced positive topline results from its Phase 1b/2a trial of AP-SA02 for S. aureus bacteremia.

Qeen Biotechnologies (in partnership with Cellexus, CPI, University of Exeter, NRC Canada, and Unity Health Toronto) was awarded a $2M CAD grant through the Canada–UK: Biomanufacturing of Biologics and Advanced Therapies program to develop

Huge milestone alert! BiomX has announced successful Phase II clinical trial results for their BX211 phage product against diabetic foot osteomyelitis! Subscribe to the Podovirus podcast to learn more — we'll be interviewing BiomX CEO Jona

Proteon Pharmaceuticals has announced the registration of its Salmonella phage-based chicken feed product, BAFASAL PRO, in Brazil! This is Proteon’s third product approval in Brazil, and second in the last year!

Qeen Biotechnologies (Gatineau, Quebec) has announced the opening of its new 4,800 sq ft manufacturing facility designed for phage production, with operations starting as of September 2024.

Landman.Bio is a new company advancing sustainable phage-based solutions for combating bacterial infections in crops, leveraging over two decades of research from KU Leuven.

Cytophage Technologies Ltd. have shared the recording of their first investor call since becoming a public company.

HYpharm GmbH and the German Center for Infection Research announced that their phage lysin HY-133 has entered phase I clinical trials. HY-133 aims to prevent nasal colonization by MRSA. The trial is conducted at the University Hospital of T

Actiphage TB, a novel phage-based TB diagnostic developed by PBD Biotech, has been recognized as a semi-finalist in the ADLM 2024 Disruptive Technology Awards.

Intralytix has received Safe Quality Food (SQF) certification for food manufacturing, becoming the only phage company to attain such recognition.

Cytophage, a Canadian phage biotech, recently made its debut on the Toronto Stock Exchange (TSX), and just announced that they’ve completed R&D on their OvaPhage product, to be sprayed over chicken eggs to reduce Salmonella, Escherichia, an

BiomX got orphan drug designation from the FDA for its BX004 phage cocktail for CF P. aeruginosa. This helps lower the cost and risk of drug development through extended exclusivity, lower filing fees and access to grants.

L'Oréal has acquired Danish probiotic and microbiome research company Lactobio.

Yves Briers will head up Obulytix, a new company based on the phage lysin-based platform leveraging AI to tackle bacterial infections he co-developed at Ghent University and KU Leuven. Obulytix has already attracted $4 M Euro investment fro

Eligo Bioscience has raised $30 million to advance and test their CRISPR-based medicine for acne vulgaris and develop their platform for other diseases. Congrats Eligo!

BiomX announced positive results from their Phase 1b/2a trial evaluating BX004, a P. aeruginosa phage cocktail, in cystic fibrosis patients. They saw clinical improvement in pulmonary function and reduced bacterial burden, paving the way fo

Oxford Silk Phage Technology, in collaboration with the University of Exeter and the University of Hertfordshire, has been awarded 2 million British pounds via a new Collaborative Innovate UK Biomedical Catalyst grant. The funds will accele